Loading...
Market
What will be the market share of the AI-based gBRCA pre-screening tool in genetic testing by December 31, 2025?
2
Resolution / Starting Odds
0-10% • 25%
11-25% • 25%
26-50% • 25%
51%+ • 25%
Market research reports, official announcements from Owkin or AstraZeneca
Story
Owkin and AstraZeneca Partner to Develop AI-Based gBRCA Breast Cancer Pre-Screening Tool
Oct 2, 2024, 02:17 PM
Owkin has announced a new partnership with AstraZeneca to develop an AI-powered pre-screening solution for gBRCA mutations (gBRCAm) in breast cancer. This tool aims to simplify genetic testing by analyzing digitized pathology slides to identify BRCA1 and BRCA2 mutations. The initiative seeks to accelerate and expand access to gBRCA testing, which many patients may not currently receive. The partnership was announced on October 2, 2024.
View original story
Similar markets
Less than 10% • 33%
10% to 25% • 33%
More than 25% • 33%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
No change • 25%
Decrease • 25%
Market share increases • 25%
Market share remains the same • 25%
Market share decreases • 25%
Foresight exits cancer-detection market • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31%+ • 25%
Less than 10% • 25%
10%-25% • 25%
25%-50% • 25%
More than 50% • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
PrecivityAD2™ dominates (>50%) • 25%
Sunbird Bio dominates (>50%) • 25%
Both share equally (~50% each) • 25%
Other diagnostic tests dominate • 25%
Below 5% • 25%
5%-10% • 25%
10%-15% • 25%
Above 15% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Yes • 50%
No • 50%
Guardant Health becomes the market leader • 25%
Guardant Health is among the top 3 • 25%
Guardant Health remains in the top 5 • 25%
Guardant Health does not make it to the top 5 • 25%